Introduction
============

Up to the last decade of the last century, open surgery was the procedure of choice for abdominal aortic aneurysm (AAA) repair. Today, however, a minimally invasive endovascular procedure can be performed. Randomised trials show that short-term survival is better after endovascular abdominal aortic aneurysm repair (EVAR) than after open AAA repair \[[@B1],[@B2]\]. After 2 years of follow-up, the total cumulative mortality in both groups is the same owing to excess mortality in the endovascularly treated group \[[@B3],[@B4]\]. Randomised trials provide generally good evidence of causal effects of treatments, but the quality of evidence on the risk of adverse events is less satisfactory. This may often be the result of the selection of relatively healthy patients and the limited length of follow-up.

Extensive and long-lasting follow-up screening is generally required after EVAR. These extensive follow-up examinations may be a considerable burden for patients and health care providers, but they are necessary for early detection of postoperative complications \[[@B5],[@B6]\]. Most complications are graft related and include graft migration, endoleak, graft thrombosis and AAA rupture. Rehospitalisation and re-intervention is necessary to treat many of these complications. Two European registries have reported a 3% risk of complications per year and a 10% risk of re-interventions per year \[[@B7]-[@B9]\]. Counterintuitively, registry data have shown that the risk of complications is significantly lower in patients who missed at least one follow-up visit compared with patients who attended all visits \[[@B10]\]. It is likely that these results are the consequence of selective surveillance in patients who are at increased risk for complications. Currently, no agreement exists on the optimal post-procedural surveillance regimen and the impact of frequent follow-up visits on the risk of complications after EVAR \[[@B11]-[@B13]\].

Evidence regarding the risk of complications after EVAR and predictors of these risks is lacking. Better insight into risk factors for complications after EVAR may lead to improvements in the efficiency of follow-up and patient selection. The aim of this study is to provide more insight into determinants of prognosis after EVAR by unique means: a meta-analysis of case reports.

Data sources and study selection
--------------------------------

The PubMed-Medline database was searched for case reports published up to January 2006. The following search string was used: (((\'aorta\' *and*\'aneurysm\') *or*(\'Aortic Aneurysms, Abdominal\' \[MESH\])) *and*\'endovascular\' *and*\'Case Reports\' \[pt\]).

Titles, abstracts and full-text publications were obtained and screened for original data on adverse events after EVAR. Exclusion criteria were: 1, non-abdominal aneurysm; 2, inflammatory abdominal aortic aneurysm; 3, AAA rupture treatment. No language restrictions were applied. Full-text versions were obtained of all remaining articles.

Data extraction and quality assessment
--------------------------------------

The following data about risk factors were extracted from the selected articles: age, gender, AAA diameter, comorbidities, endograft brand and type, one or more follow-up visits being missed and refusal of a re-intervention by the patient. The following data about clinical endpoints were documented: death, device-related complications and non-device-related complications. When a patient experienced more than one complication, all complications were documented. Device-related complications included: AAA rupture, endoleak types I, II, III, IV and V (endotension), graft infection, graft migration, graft thrombosis, graft kinking, stent wire fracture and technical mal-deployment. Non-device-related complications included cardiac, pulmonary and renal complications, fistula, ischaemia, multiple organ failure and other non-device-related complications.

Data synthesis and analysis
---------------------------

Risk factors were associated with clinical endpoints by cross-tabulation. Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated using Episheet \[[@B14]\]. A P value of less than 0.05 was considered significant.

Case presentation
=================

The Medline search strategy resulted in a total of 353 case reports. After excluding articles on the basis of the inclusion and exclusion criteria, 113 case reports remained which reported original data about 173 patients who had undergone endovascular AAA repair.

Table [1](#T1){ref-type="table"} shows baseline characteristics of the study population. Eighty percent of the patients were male (*N*= 138), 14% female (*N*= 24) and no data were available about gender in 6.3% of the patients (*N*= 11). The mean AAA diameter prior to device implantation was 60 mm (standard deviation 11; range 42 to 95). The AAA diameter was smaller than 5.5 cm in 25% of all patients (*N*= 43). The mean age was 73 years (range: 52 years to 93 years).

###### 

Characteristics of the study population

                                                              ***N*or mean ± standard deviation**   **Percentage or range**
  ----------------------------------------------------------- ------------------------------------- -------------------------
  **Gender**                                                                                        
   Male                                                       138                                   80%
   Female                                                     24                                    14%
   Unspecified                                                11                                    6%
  **Age at operation (years)**                                72.47 ± 7.62                          (52 to 93)
   50 to 59 years                                             7                                     4%
   60 to 69 years                                             41                                    24%
   70 to 79 years                                             83                                    48%
   80 to 89 years                                             26                                    15%
   90 to 99 years                                             1                                     1%
   Unspecified                                                15                                    9%
  **Comorbidities**                                                                                 
   Diabetes                                                   5                                     3%
   Smoking                                                    5                                     3%
   Hypertension                                               21                                    12%
   Hypercholesterolaemia                                      6                                     3%
   Cardiac status                                             25                                    14%
   Obesity                                                    7                                     4%
   Stroke                                                     5                                     3%
   Pulmonary status                                           21                                    12%
   Renal status                                               10                                    6%
   Other\*                                                    23                                    13%
   Peripheral vascular disease                                7                                     4%
   Carotid disease                                            1                                     1%
  **Number of comorbidities**                                                                       
   0 or unspecified                                           114                                   66%
   1 or 2                                                     26                                    15%
   ≥3                                                         33                                    19%
  **AAA diameter**                                            59.78 ± 11.04                         42 to 95
  **Incomplete follow-up adherence**^†^                       8                                     5%
   **Time interval between EVAR and complication (months)**   13.73 ± 16.11                         0 to 85
   Perioperative, up to 24 hours                              31                                    18%
   Initial, up to 30 days post-operative                      28                                    16%
   Short term, 30 days to 6 months                            15                                    9%
   Early mid-term, 6 months to 2 1/2 years                    62                                    36%
   Late mid-term, 2 1/2 years to 5 years                      23                                    13%
   Long term, \> 5 years                                      4                                     2%
   Unspecified                                                10                                    6%

\*Other comorbidities that were described in the case reports included: active hepatitis C, alcohol abuse, arteriocaval fistula, bilateral gunshot injury, chemoradiation, cholangitis, Crohn\'s disease, factor VII deficiency, degenerative joint disease of lumbar spine, hemicolectomy, \'hostile\' abdomen, hyperthyreoidectomy, hypoplastic marrow, liver cirrhosis, lymphoma, multiple gastrointestinal and urogenital operations, non-Hodgkin\'s lymphoma, pancreatoduodenectomy, pancytopenia, polycystic kidney disease, prostate cancer, rectal cancer, sigmoid resection and renal transplantation. †\'Incomplete follow-up adherence\' is defined by the patient missing one or more follow-up visits or refusing a re-intervention. AAA, abdominal aortic aneurysm; EVAR, endovascular abdominal aortic aneurysm repair; SD, standard deviation.

The median time from device implantation to death, rupture or other complications was 8.5 months with a range of 0 to 85 months. Table [2](#T2){ref-type="table"} provides an overview of the reported complications in our study population. A fatal outcome was reported for 15% of all patients (*N*= 26). AAA rupture caused death in 50% of these patients (*N*= 13). Death was directly or indirectly related to EVAR in the other 50% (*N*= 13), which mostly occurred after complications of conversion to open AAA repair or aortoduodenal fistula.

###### 

Complications after endovascular abdominal aortic aneurysm repair

  **Complication**                ***N***   **Percentage**
  ------------------------------- --------- ----------------
  **Device related**                        
  Endoleak                        98        57%
   Type I                         25        14%
   Type II                        26        15%
   Type III                       12        7%
   Type IV                        0         0%
   Type V/endotension             5         3%
   Unspecified                    30        17%
  Kinking of stent graft          9         5%
  Thrombosis of stent graft       19        11%
  Graft migration                 26        15%
  Stent wire fracture             12        7%
  Graft infection                 5         3%
  Technical deployment problems   13        8%
  **Non-device related**                    
  Multiple organ failure          8         5%
  Cardiac                         7         4%
  Pulmonary                       8         5%
  Renal                           8         5%
  Fistula                         11        6%
  Ischaemic, embolic              25        14%
  Other\*                         6         3%
  **Secondary intervention**      144       83%
  Open conversion                 57        33%
  **AAA rupture**                 38        22%
  **Fatal course**                26        15%

\*Other complications that were described in the case reports included: heparin-induced thrombocytopenia, metal-induced pruriginous dermatitis, peri-aortitis with ureteral obstruction, upper gastric intestinal bleed, sloughing of scrotal skin and impotence. AAA, abdominal aortic aneurysm.

AAA rupture occurred in 22% of all patients (*N*= 38). The AAA rupture was fatal in 34% of these patients (*N*= 13) and non-fatal in 66% of these patients (*N*= 25). Interestingly, in 50% of the patients with an AAA rupture (*N*= 19), no prior endoleak was detected during regular postoperative follow-up. Other complications that were reported for patients in the total study population included endoleaks in 52%, graft thrombosis in 11% and graft infections in 3%. Technical device-related complications, including mal-deployment of the graft, graft migration, graft kinking and stent wire fracture, occurred in 35% of all patients (*N*= 61). Non-device-related complications occurred in 42% of all patients (*N*= 73).

One or more re-interventions were performed in 83% of all patients. The main indications for re-intervention included embolisation, conversion to open AAA repair, clipping of arteries, operative exploration, thrombectomy and thrombolysis. Table [3](#T3){ref-type="table"} shows the calculated RRs and 95% CIs of associations of clinically relevant factors with subsequent mortality and rupture after EVAR. The risk of mortality was higher for female patients than for male patients (RR 2.9, 95% CI 1.4 to 6.0). A patient missing one or more follow-up visits or refusing a re-intervention appeared to increase the risk of both rupture and mortality (RR 4.7, 95% CI 3.1 to 7.0; and RR 3.8, 95% CI 1.7 to 8.3, respectively). The presence of at least three comorbidities was also significantly associated with rupture and mortality (RR 1.6, 95% CI 0.9 to 2.9; and RR 2.1, 95% CI 1.0 to 4.7, respectively). Larger AAA diameter and higher age appeared to be associated with increased AAA rupture risks, although none of the associations reached significance.

###### 

Risk ratios and 95% confidence intervals of associations of clinically relevant factors with subsequent mortality and rupture after endovascular abdominal aortic aneurysm repair

                                        **Death or rupture**   **Rupture**   **Death**                                                                                
  ---------------------- -------------- ---------------------- ------------- ----------------- --------------- ---------- ---------------- --------------- ---------- -----------------
                         ***N*total**   ***N*events**          **Risk**      **RR (95%CI)**    ***N*events**   **Risk**   **RR (95%CI)**   ***N*events**   **Risk**   **RR (95%CI)**
                                                                                                                                                                      
  **Gender**                                                                                                                                                          
   Male                  138            36                     0.26          \-                29              0.21       \-               16              0.12       \-
   Female                24             11                     0.46          1.8 (1.0;2.9)\*   6               0.25       1.2 (0.6;2.6)    8               0.33       2.9 (1.4;6.0)\*
   Unspecified           11             4                      0.36          1.4 (0.6;3.2)     3               0.27       1.3 (0.5;3.6)    2               0.18       1.6 (0.4;6.0)
                                                                                                                                                                      
  **Age at operation**                                                                                                                                                
                                                                                                                                                                      
   50 to 59 years        7              2                      0.29          \-                1               0.14       \-               2               0.29       \-
   60 to 69 years        41             10                     0.24          0.9 (0.2;3.0)     9               0.22       1.5 (0.2;10)     3               0.07       0.3 (0.1;1.3)
   70 to 79 years        83             24                     0.29          1.0 (0.3;3.4)     15              0.18       1.3 (0.2;8.2)    12              0.14       0.5 (0.1;1.8)
   80 to 89 years        26             10                     0.38          1.3 (0.4;4.8)     9               0.35       2.4 (0.4;16)     6               0.23       0.8 (0.2;3.2)
   90 to 99 years        1              1                      1.00          3.5 (1.1;11)\*    1               1.00       7.0 (1.1;43)\*   1               1.00       3.5 (1.1;11)
   Unspecified           15             4                      0.27          0.9 (0.2;3.9)     3               0.20       1.4 (0.2;11)     2               0.13       0.5 (0.1;2.7)
                                                                                                                                                                      
  ***N*comorbidities**                                                                                                                                                
                                                                                                                                                                      
   0 or unspecified      114            27                     0.24          \-                24              0.21       \-               13              0.11       \-
   1 or 2                26             8                      0.31          1.3 (0.7;2.5)     3               0.12       0.5 (0.2;1.7)    5               0.19       1.7 (0.7;4.3)
   ≥3                    33             16                     0.48          2.0 (1.3;3.3)\*   11              0.33       1.6 (0.9;2.9)    8               0.24       2.1 (1.0;4.7)\*
                                                                                                                                                                      
  **AAA diameter**                                                                                                                                                    
                                                                                                                                                                      
   40 to 49 mm           15             5                      0.33          \-                3               0.20       \-               3               0.20       \-
   50 to 59 mm           67             19                     0.28          0.9 (0.4;1.9)     13              0.19       1.0 (0.3;3.0)    11              0.16       0.8 (0.3;2.6)
   60 to 69 mm           36             10                     0.28          0.8 (0.3;2.0)     8               0.22       1.1 (0.3;3.6)    5               0.14       0.7 (0.2;2.5)
   70 to 79 mm           14             8                      0.57          1.7 (0.7;4.0)     7               0.50       2.5 (0.8;7.8)    2               0.14       0.7 (0.1;3.7)
   \> 80 mm              11             4                      0.36          1.1 (0.4;3.1)     3               0.27       1.4 (0.3;5.5)    3               0.27       1.4 (0.3;5.5)
   Unspecified           30             5                      0.17          0.5 (0.2;1.5)     4               0.13       0.7 (0.2;2.6)    2               0.07       0.3 (0.1;1.8)

AAA, abdominal aortic aneurysm; CI, confidence interval; RR, risk ratio. \*P value less than 0.05.

Discussion
==========

Female gender, comorbidities, missing one or more follow-up visits or refusal of a re-intervention by the patient appear to significantly increase the risk for mortality after EVAR. No prior endoleak was discovered during follow-up in 50% of the patients with an AAA rupture after EVAR. Larger aneurysm diameter, higher age and comorbidities may also increase the risk for AAA rupture after EVAR, although these associations could not be established significantly.

To the best of the authors\' knowledge this is the first meta-analysis of case reports. Case reports do not provide strong causal evidence because they report only a small number of patients. Case reports can provide relevant information, notably on long-term complications in the realm of patients actually seen and treated in daily practice. Although they could be emphasising the bizarre \[[@B15]\], case reports are considered an important cornerstone for medical progress. This type of article can help to detect specific patterns of patient outcomes, particularly with regard to clinically important and rare adverse events and complications \[[@B16]\]. Case reports may therefore offer valuable information about the mechanisms of the development of complications.

The aim of our study was to review which patient, disease or procedural characteristics predict complications after EVAR. The selection of case reports about patients with complications after EVAR may have resulted in a cohort of patients who are at high risk for complications, irrespective of the device or the procedure. Therefore, one may question whether these extraordinary patients may have brought the complications to the device or procedure. Although patients who were included in this study may represent the odd and extraordinary cases, they clearly are patients who are seen in practice. For ethical considerations and reasons of efficiency, these odd and extraordinary cases are generally excluded from randomised trials and cohort studies. The risk factors derived from the presented cohort of case reports are similar to those reported in prognostic cohort studies. Hence, our results contribute to the robustness of the reported predictors.

Unfortunately, the documentation of clinical data was not performed according to a standardised protocol \[[@B17]\] in many case reports. As data in our study were limited to data that were presented in the selected case reports, a considerable amount of data was missing. The percentages of missing data in our study were 6.3% for gender, 8.7% for age, 5.8% for the time interval between EVAR and complication, and 17% for initial AAA diameters. Univariate analyses were performed to calculate associations between putative risk factors and subsequent clinical outcomes for different subgroups on the basis of the available data and also for the group of patients with missing and/or unspecified data. Comorbidities were described in 34% of all patients. From our point of view, this percentage can best be regarded as the minimum value of the number of patients with comorbidities, because under-reporting of comorbidities is likely in the other 66%. Missing data is a disadvantage which is inevitably linked with the unique approach, and should be regarded carefully when interpreting the results.

Several studies have compared mortality and morbidity risks in men and women after EVAR. Two national database studies in the US have shown that mortality after EVAR is significantly 2.0 to 2.5 times higher in women than in men \[[@B18],[@B19]\]. The EUROSTAR study indicated that female gender was a significant risk factor for endoleak \[[@B20]\]. In addition to significantly reduced sizes of iliacal arteries, women are more likely to have a shorter, more dilated and more angulated proximal aortic neck, which may lead to proximal endoleak and graft migration \[[@B21]\]. Female patients also have a higher risk of abortion of the initial EVAR procedure and mal-deployment of the endograft \[[@B22]\]. Wolf et al. showed that women had significantly more intra-operative complications compared with men. They hypothesised that this was related to differences in arterial access \[[@B23]\]. Nordness et al. showed that women were more likely to have significant arterial dissections during EVAR. One-month mortality risks were 12% in female and 0% in male patients (P = 0.02). One-month complication risks were 41% in women and 15% in men (P = 0.02) \[[@B24]\]. Ouriel et al. found no differences between men and women in perioperative and mid-term mortality. However, they demonstrated a higher risk for graft-limb occlusions in women than in men \[[@B25]\].

The impact of comorbidities on the risk of mortality after EVAR has been described by several authors. Azizzadeh et al. showed that patients with a low glomerular filtration rate (GFR) faired significantly worse than patients with a better GFR \[[@B26]\]. Biancari et al. showed that survival was significantly different among tertiles of the Glasgow Aneurysm Score, which is a tool for measuring the fitness of the patient for surgery (P \< 0.001). Patients with a high score and extensive comorbidities had a significantly lower 5-year survival rate than the other patients \[[@B27]\]. Chaikof et al. categorised patients into a high-risk group (*N*= 123) and a low-risk group (*N*= 113) according to the clinical condition of the patient. The 2-year survival was 73.5% for high-risk patients and 85.8% for low-risk patients (P = 0.035 \[[@B28]\]. Riambau et al. showed that patients with a poor medical condition had a significantly lower 1-year survival after EVAR compared with relatively fit patients: 83% versus 93% (P \< 0.001). Diabetes mellitus appears to influence mortality considerably \[[@B29]\]. Zannetti et al. divided patients in subgroups according to the American Society for Anesthesiology (ASA) classification. Cumulative survival was 89% in the ASA \< IV and 76% in the ASA IV group (P = 0.004) after 3 years of follow-up \[[@B30]\]. These reports, in combination with our results, underscore the impact of comorbidities on mortality and morbidity after EVAR.

Missing one or more follow-up visit appeared to increase the risk of complications in our study. As far as we know, this has never been described before. The EUROSTAR study showed counter-intuitively that the risk of complications was significantly higher in patients with a perfect follow-up adherence. Compliance with follow-up screening in their study appeared to be biased, however, because high-risk patients, including smokers, patients with hyperlipidaemia, and patients who were unfit for open surgery or general anaesthesia had the best follow-up adherence \[[@B10]\]. Therefore, extensive follow-up screening and re-interventions are still required after EVAR.

Conclusion
==========

Although a meta-analysis of case reports has some clear methodological drawbacks, it offers unique opportunities. The risk factors for complications after endovascular AAA repair that are presented in this document are similar to those that are presented in prognostic cohort studies. Female gender and the presence of comorbidities appear to increase the risk of mortality after EVAR. Larger AAA diameter, higher age and multimorbidity at the time of surgery increase the risk for rupture and other complications following EVAR. These risk factors deserve attention in future well-designed follow-up studies.

Abbreviations
=============

AAA: abdominal aortic aneurysm; ASA: American Society for Anesthesiology; CI: confidence interval; EVAR: endovascular abdominal aortic aneurysm repair; GFR: glomerular filtration rate; RR: risk ratio; SD: standard deviation.

Competing interests
===================

The authors declare that they have no competing interests.

Authors\' contributions
=======================

Each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

Acknowledgements
================

No funding or other financial or material support was used for this study. There were no sponsors involved with the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
